NHS to Offer Weight Loss Drug Wegovy to Over a Million Heart Disease Patients

In Brief

The rollout aims to reduce cardiovascular risks and improve health outcomes for patients with obesity and heart disease.

Key Facts

• Wegovy can now be prescribed to help with weight loss or reduce the risk of major cardiovascular events.
• More than a million people with heart disease are expected to be eligible for the weight loss jab.
• The drug is intended to prevent heart attacks or strokes in patients with heart disease.
• The NHS will offer the anti-obesity jab to people in England at risk of further heart attacks.
• Experts have described the announcement as a 'win-win' for patients.

What Happened

The NHS announced that more than a million people with heart disease in England will be offered the weight loss drug Wegovy to help reduce the risk of heart attacks and strokes.

Why It Matters

This initiative represents a significant public health measure aimed at addressing obesity-related complications and reducing the burden of cardiovascular disease in England.

What's Next

Eligible patients are expected to begin receiving prescriptions for Wegovy. Health authorities will monitor the impact on cardiovascular outcomes and patient health.